Global Kinase Inhibitors Market – Industry Trends and Forecast to 2029

Kinase Inhibitors Market Analysis and Size

The kinase inhibitors market is expected to witness significant growth during the forecast period. The dynamic field of cancer R&D is permitting an improvement to the specialization in kinases, which play an essential role as mediators in many types of cancer and other diseases. Latest advancements are being made in anti-angiogenesis receptor tyrosine kinase inhibitors used for cancer treatment. Several companies are growing their efficacy in molecular modeling to accelerate drug discovery for fibrosis and other diseases. COVID-19 also had a major impact on the market growth.

 Data Bridge Market Research analyses a growth rate in the global kinase inhibitors market in the forecast period 2022-2029. The expected CAGR of global kinase inhibitors market is tend to be around 7.2% in the mentioned forecast period. The market was valued at USD 56.1 billion in 2021, and it would grow upto USD 97.84 billion by 2029. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Kinase Inhibitors Market Scope and Segmentation

Market Definition

Kinase inhibitors are the drug class that restricts the action of kinases by adding a phosphate group to protein so that function of kinase gets disrupted. Kinases are involved in several cellular activities, including cell proliferation, differentiation, cell cycle, and cell apoptosis. Their inhibition can negatively impact a cell, causing it to die or fail to function properly. Most important types are therefore used to treat a diversity of diseases where this type of disruption is important to be involved, such as cancer, diabetes, and inflammation.

Global Kinase Inhibitors Market Dynamics

Drivers

• Technological Innovations

The kinase inhibitors market is projected to expand during the forecast period. Innovations such as artificial intelligence are transforming the market for kinase inhibitors. For instance, the U.S. biotechnology startup Insilico Medicine revealed its deep learning system, which can identify potential treatments for fibrosis with the help of DDR1 (Discoidin Domain Receptor 1) kinase inhibitors. Besides this, several healthcare companies are capitalizing on generative adversarial networks (GANs) to produce novel molecular structures with specified properties. Similarly, deep learning is letting companies with the rapid identification of potent DDR1 kinase inhibitors. Thus, all these advancements lead to the market growth.

• Increasing Prevalence of Cancer

Rise in the occurrence of cancer patients among the population is the primary cause of the growth of the global kinase inhibitors market. As per the Cancer Research UK data, about 17 million new cancer cases were reported globally in 2018 and almost 27.5 million new cancer cases are likely to be observed worldwide by 2040. Thus, this increasing prevalence of cancer is demanding more kinase inhibitors and which in return is boosting the market growth.

Opportunities

• Growing Adoption of Biochemistry

Novel assays and profiling techniques are serving companies to develop improved kinase inhibitors for drug development. The discovery of new kinase inhibitors is projected to improve biochemical, cellular, and in vivo assays that are assisting in offering new therapeutic targets. Companies in the kinase inhibitors market are growing R&D to gain expertise in cell signaling for the huge development of new drugs. Several companies are making more and more efforts to gain information on biochemical and biophysical assays to study the potency and selectivity of kinase inhibitors. Thus, these developments are creating huge efforts for the market expansion.

• Expanding Indications of kinase inhibitors

Increasing indications of existing and pipeline kinase inhibitors also create many opportunities for market growth. For instance, BCR-ABL TKIs, which were earlier approved for treating CML, are now indicated to treat acute lymphoblastic leukemia (ALL) and gastrointestinal tumors. Likewise, EGFR TKIs are approved for a collection of indications such as pancreatic cancer, breast cancer, and non-small cell lung cancer.

 Restraints/Challenges

• Lack of skilled professionals

The lack of qualified personnel who are unable to treat the patients with appropriate treatments could limit the growth of the global kinase inhibitors market over a forecast period.

• High Cost

The R&D has higher costs and complex approval processes by respective governments, which restricts the market's growth significantly. Furthermore, the high development cost of drugs causes the higher market price of the drug post-approval. Therefore, the cost of the treatment has been limiting the market growth up to a certain level.

This kinase inhibitors market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the kinase inhibitors market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Kinase Inhibitors Market

COVID-19 has left a major global public health crisis which has impacted practically every business. Shift from healthcare infrastructure towards managing COVID-19 has led to drug launch withdrawals and delays in clinical trials.

In the post-pandemic era, the biotechnology and pharmaceutical industries are estimated to witness enormous future growth due to the demand for vaccine and treatment drugs for COVID-19. It has been witnessed that the non-receptor tyrosine kinase inhibitors result in the highest revenue share of the market in 2021 and are projected to lead the market in the post-COVID-19 period due to their high effectiveness in the treatment of autoimmune and inflammatory skin diseases such as rheumatoid arthritis.

Recent Developments

• In September 2020, Boehringer Ingelheim announced the final analysis from GioTag. This is a real-world retrospective, observational study which showed that Giotrif/Gilotrif followed by osimertinib witnessed median overall survival (OS) of 37.6 months in patients with EGFR mutation-positive Non-Small-Cell Lung Cancer (NSCLC).
• In February 2021, Novartis received the Breakthrough Therapy designation (BTD) grant by the U.S. FDA for asciminib to treat adult patients having Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), which was earlier treated with 2 or more tyrosine kinase inhibitors (TKIs).
• In November 2021, HUTCHMED and AstraZeneca started SACHI Phase III Trial of ORPATHYS and TAGRISSO combination in specific lung cancer patients in China after progression on EGFR inhibitor therapy.

Global Kinase Inhibitors Market Scope

The global kinase inhibitors market is segmented on the basis of type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Tyrosin Kinase Inhibitors
• VEGFR
• PDGFR
• EGFR
• ALK
• HER2
• Mulikinase Inhibitors
• Cabozantinib
• Imatinib
•  Lenvatinib
• Regorafenib
• mTOR Kinase Inhibitors
• Sirolimus
• Everolimus
• Temsirolimus
• Others

Route of Administration

• Oral
• Parenteral
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Kinase Inhibitors Market Regional Analysis/Insights

The global kinase inhibitors market is analysed and market size insights and trends are provided by type, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global kinase inhibitors market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America has been witnessing a positive growth for global kinase inhibitors market throughout the forecasted period due to the increase prevalence of cancer and large availability of treatment options for cancer patient.

Asia-Pacific dominates the market due to the government funding and awareness.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Kinase Inhibitors Market Share Analysis

The global kinase inhibitors market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global kinase inhibitors market

Key players operating in the global kinase inhibitors market include:

• Novartis AG (Switzerland)
• Endo International Inc (Ireland)
• Teva Pharmaceutical Industries Ltd (Israel)
• Glenmark Pharmaceuticals Ltd (India)
• Cipla Inc (India)
• Dr Reddy's Laboratories Ltd (India)
• Abbott (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Pfizer Inc (U.S.)
• Lupin (India)
• Takeda Pharmaceutical Company Limited (Japan)
• Akorn, Incorporated (U.S.)
• Torrent Pharmaceuticals Ltd. (India)
• Amneal Pharmaceuticals LLC. (U.S.)
• Astellas Pharma Inc. (Japan)
• Sierra Oncology, Inc (Canada)

SKU-54370